
    
      This will be a Phase 3, randomized, double-masked, parallel arm, positive-controlled
      non-inferiority study, in which up to 250 subjects (approximately 125 subjects per treatment
      arm) will be enrolled at up to 60 clinical sites. Patients with non-infectious anterior
      segment uveitis who are interested in participating in the study will be provided an informed
      consent form prior to screening. Screening/Baseline procedures which include BCVA, slit lamp
      examination, fundus exam, IOP by tonometry will be used to determine eligibility.
    
  